Diabetic Patient Adherence to Yearly Influenza Vaccination in Northern Greece

Dimitrios Pilalas 1, Stylianos Daios 2, Melina Kachrimanidou 3, Georgia Kaiafa 2, Soultana Avgeri 4, Eleftheria Ztriva 2, Anastasia Kontana 2, Stergiani Karamari 2, Eleni Karlafti 6, Ilias Kanellos 2, Christos Savopoulos 2

1. First Propedeutic Department of Internal Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, GRC 2. First Propedeutic Department of Internal Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, GRC 3. First Department of Microbiology, University General Hospital of Thessaloniki AHEPA, Thessaloniki, GRC 4. Bloodbank, Agios Pavlos Hospital, Thessaloniki, GRC 5. Second Department of Paediatrics, University General Hospital of Thessaloniki AHEPA, Thessaloniki, GRC 6. First Propedeutic Department of Internal Medicine, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, GRC

Corresponding author: Christos Savopoulos, chrisavpoulos@gmail.com

Abstract

Background
Influenza virus infection is associated with increased morbidity and mortality in patients with diabetes mellitus. Public health authorities recommend yearly vaccination of diabetic patients against seasonal influenza.

Methods
We surveyed to define the adherence to influenza vaccination and associated factors among diabetic patients in Thessaloniki, Greece. Predictors of adherence to yearly influenza vaccination were assessed with logistic regression models.

Results
A total of 206 patients were enrolled, with 47.1% reporting yearly vaccination against influenza (95% confidence interval, CI: 40.3% to 53.9%). In univariate models, the absence of additional indications for vaccination was associated with a decreased likelihood of vaccination uptake (OR: 0.29, 95% CI: 0.11 to 0.68, p=0.007); older diabetic patients were more likely to receive influenza vaccination (34% increase per 10 years of age). These associations were attenuated in multivariable analysis.

Conclusion
Our study demonstrates a significant gap in influenza vaccination coverage rate in diabetic patients. Our data could be extrapolated to enhance the uptake of vaccines against SARS-CoV-2: emphasis should be placed on patient education.

Keywords: vaccination, diabetes, influenza, flu, adherence, risk factors

Introduction
Seasonal influenza is caused by influenza A or B viruses affecting 5-15% of the population worldwide yearly [1]. Usually, seasonal influenza virus infections are associated with mild and self-limiting respiratory symptoms. However, complications may arise, resulting in increased morbidity and mortality. Host factors impact the severity of the disease: complications predominantly affect the elderly and patients with comorbidities such as diabetes mellitus (DM) [1]. Pro-coagulant effects caused by the influenza infection may exacerbate the increased risk of vascular disease associated with DM [1,2].

Impaired glucose metabolism is associated with dysfunction of innate and adaptive immunity. Public health authorities and scientific communities recommend the vaccination of patients with DM against seasonal influenza [2]. Nevertheless, the European Union (EU) Council 2009 goal to reach a vaccination coverage rate (VCR) of at least 75% across the European Union (EU) for at-risk populations has not been attained with only a few countries approaching the desired rate [3,4].

A high-level influenza VCR in the setting of the COVID-19 pandemic is a sine qua non to minimize the burden influenza would exert on hospitals. Diabetic patients are at high risk for severe complications and hospitalization, including increased mortality from SARS-CoV-2, and should be prioritized as a target population for vaccination [5,6]. Achieving optimal glucose control and taking all necessary precautions is of
utmost importance to avoid excess morbidity and mortality and optimize healthcare resource allocation [6].

We aimed to estimate the influenza VCR among people with diabetes linked to medical care in our region and to identify factors associated with yearly seasonal influenza vaccination and missed opportunities.

**Materials And Methods**

A structured questionnaire was administered through telephone interviews conducted by one co-author (S.A) for four months. Patients eligible for the study were adults diagnosed with diabetes and followed in outpatient clinics of Agios Pavlos and the AHEPA University Hospital in Thessaloniki, Greece.

The questionnaire included demographic information (gender, age, marital status, number of children, if any, level of education, insurance status, and residence in urban, semi-urban, or rural areas) and diabetes care and patient comorbidities. Further questions addressed body mass index, smoking status, alcohol consumption. The respondents were asked if they were vaccinated yearly against seasonal influenza and to identify who proposed the vaccination during the study season. The final set of questions concerned aspects of diabetes care such as having the same doctor for the treatment of diabetes, the duration of the patient- doctor relationship, the number of visits per year, and the last HbA1c measurement. The documents required by the European and National Bioethics Committee were signed by the scientific council and the responsible departments.

Binomial 95% confidence intervals were calculated for proportions. Predictors of yearly vaccination against influenza were evaluated in univariate logistic regression models; those significantly associated with yearly vaccination (p<0.05) were tested in a multivariable logistic regression model by forced entry. All analyses were conducted in R version 4.0.0 (packages binom and stats) [7].

**Results**

A total of 206 adult diabetic patients were included. The mean age of the patient population was 67.7 years, and the male to female ratio was 1:1.4. All patients were insured. More than half of the patients lived in urban areas (65%) and had not received secondary education (62.6%). The demographic characteristics of the patient population are summarised in Table 1. Among survey participants, 83.3% had at least one child. The median body mass index was 29 (interquartile range, IQR: 25.7-33.2). Most patients were non-smokers (78.6%) and refused regular alcohol intake (95.6%). Approximately 86% of patients were diagnosed with DM Type II, and only one out of three had been diagnosed with diabetes for less than 10 years. Most patients had long-lasting patient–doctor relationships (median eight years, IQR 4-15) and visited their providers frequently (median four encounters/year, IQR: 2-5). However, only 33.3% had on target HbA1c levels.
Patients enrolled | 206
---|---
Mean age (standard deviation) | 67.7 (13.6)
Gender (%) | 
Male | 87 (42.2%)
Female | 119 (57.8)
Level of education in years (%) | 
Less than 6 | 129 (62.7%)
7 to 9 | 21 (10.2%)
10 to 12 | 32 (15.5%)
More than 12 | 24 (11.6%)
Place of residence | 
Urban | 134 (65%)
Other | 72 (35%)
Marital Status | 
Married | 149 (72.3%)
Other | 56 (27.2%)
Unknown | 1 (0.5%)

**TABLE 1: Demographic characteristics of diabetic patients linked to healthcare enrolled in a survey of adherence to yearly vaccination against influenza in Thessaloniki, Greece.**

The majority of the patients had at least one other indication for flu vaccination except for diabetes (85.4%). Comorbidities included cardiac disease (38.8%), pulmonary disease (12.1%), malignancy (6.3%), immunosuppression (20.3%), chronic renal disease (18.4%), neurological disease (5.3%) and morbid obesity (5.9%).

In our study, the VCR against influenza yearly was 47.1% (97/206, 95% confidence interval, CI: 40.3 - 53.9%). Univariate and multivariable logistic regression analysis results are reported in Table 2.

| Predictor | Univariate analysis | Multivariable analysis |
|---|---|---|
| | Odds ratio (95% confidence interval) | p-value | Odds ratio (95% confidence interval) | p-value |
| Age (per 10-year increase) | 1.34 (1.10 to 1.79) | 0.006 | 1.22 (0.90 to 1.63) | 0.15 |
| Gender (reference male) | 1.17 (0.67 to 2.04) | 0.579 | - | - |
| Level of education (reference education of less than 6 years) | 0.59 (0.33 to 1.04) | 0.072 | - | - |
| Place of residence (reference urban) | 1.20 (0.67 to 2.13) | 0.539 | - | - |
| Absence other than diabetes indication for flu vaccination (reference presence of any other indication) | 0.29 (0.11 to 0.68) | 0.007 | 0.46 (0.15 to 1.31) | 0.158 |

**TABLE 2: Predictors of yearly adherence to influenza vaccination against influenza among diabetic patients linked to healthcare, Thessaloniki, Greece**

It should be noted that among the patients who were vaccinated yearly, 53.6% reported being self-motivated.
to seek a vaccine prescription, 14.4% had the vaccination recommended by their primary care physician, and
26.8% by a specialty doctor. Notably, 5.2% of patients were vaccinated following a recommendation by their
pharmacist.

Discussion

We surveyed diabetic patients attending outpatient clinics in one tertiary and one secondary care hospital in
Thessaloniki, Greece. The yearly influenza VCR was 47.1% (95% CI: 40.3% to 55.9%). Older age and other
indications for flu vaccination were associated with an increased likelihood of vaccination against the flu in
univariate analysis, but the association was attenuated in multivariable analysis. Almost half of the patients
who reported yearly vaccination were self-conscious about the need to be vaccinated. In our sample,
specialty doctors motivated the vaccination almost two times more frequently than primary care
physicians (26.8% vs 14.4%).

Data concerning influenza VCR in populations at risk in Greece are limited, and the preponderance of the
literature concerns healthcare workers [8-10]. Available influenza VCR data from the Survey of Health,
Aging and Retirement in Europe (SHARE) program collected in 2004-05 indicate that Greece had VCR lower
than 27% in all high-risk groups [11]. In this survey, only 21.8% (95% CI: 15.1% to 28.5%) of patients with
diabetes were vaccinated against influenza with an OR of 1.07 (95% CI: 0.7 to 1.66) compared to non-diabetic
individuals [10]. In a recent nationwide study in adults older than 60, 83.6% (95% CI 80.9% to 86.4%) of
patients with diabetes reported being vaccinated against the flu versus 52.9% of diabetics over 60 reporting
yearly vaccination in our study [12]. In the study by Papagiannis et al. [12], the sample of general
practitioners was random, nationwide, geographically stratified and the patients enrolled subsequently were
a convenience sample. In contrast, our study was based on a convenience sample from two hospitals.
Nevertheless, it should be noted that the development of the primary care network in Greece does not cover
the entire population at present, especially in urban centers, as reflected by the low percentage of primary
care physicians motivating the vaccination in our study.

According to a report from the European Centre for Disease Prevention and Control in 2016-17, the
influenza VCR among patients with chronic medical conditions ranged from 15.7% to 57.1%, with data
available for only 7 of the 30 responding states [3]. Individual studies also reported VCRs below the 75%
threshold in patients with diabetes [13-16].

The finding that older age increases the likelihood of vaccination against the flu is consistent with the
literature [14,17-19], but in Europe, VCRs seem to be decreasing in the elderly [16]. Also alarming is the
finding that people with diabetes without other comorbidities seem to neglect the need for vaccination
against the flu; previous research in Greece supports our findings [20]. It should be noted that the
associations mentioned above were attenuated in multivariable analysis.

Limitations of our study include the sample’s representativeness, which may reflect a more complex patient
population than the general diabetic population, and recall bias.

Conclusions

In conclusion, our study demonstrates a significant gap in influenza VCR in diabetic patients despite official
recommendations supporting the vaccination and the fact that vaccination is provided free of charge. Our
data could be extrapolated to enhance the uptake of vaccines against SARS-CoV-2: emphasis should be
placed on patient education.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All
authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In
compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services
info: All authors have declared that no financial support was received from any organization for the
submitted work. Financial relationships: All authors have declared that they have no financial
relationships at present or within the previous three years with any organizations that might have an
interest in the submitted work. Other relationships: All authors have declared that there are no other
relationships or activities that could appear to have influenced the submitted work.

References

1. Goeijenbier M, van Sloten TT, Slobbe L, Mathieu C, van Genderen P, Beyer WE, Osterhaus AD: Benefits of flu
    vaccination for persons with diabetes mellitus: a review. Vaccine. 2017, 35:5095-101.
    10.1016/j.vaccine.2017.07.095

2. Toniole A, Cassani G, Puggioni A, Rossi A, Colombo A, Onodera T, Ferrannini E: The diabetes pandemic and
    associated infections: suggestions for clinical microbiology. Rev Med Microbiol. 2019, 30:1-17.
    10.1097/MRM.0000000000000155
3. European Centre for Disease Prevention and Control. Seasonal influenza vaccination and antiviral use in EU/EAA Member States - Overview of vaccine recommendations for 2017-2018 and vaccination coverage rates for 2015-2016 and 2016-2017 influenza seasons. Stockholm: ECDC 2018. (2018). Accessed: January 13, 2021: https://10.2900/721517.

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2019. 2019, 42:S34-45. 10.2337/dc19-S004

5. Jaklevic MC: Flu vaccination urged during COVID-19 pandemic. JAMA. 2020, 324:926-7. 10.1001/jama.2020.15444

6. Kaiafa G, Veneti S, Polychronopoulos G, et al.: Is HbA1c an ideal biomarker of well-controlled diabetes?. Postgrad Med J. 2021, 97:380-3. 10.1136/postgradmed-2020-136756

7. R Core Team (2020). R: A language and environment for statistical computing. B Foundation for Statistical Computing, Vienna, Austria. (2020). Accessed: January 15, 2021: http://www.R-project.org.

8. Maltezou HC, Maragos A, Katerelos P, Païsi A, Karageorgou K, Papadimitriou T, Pierroutsakos IN: Influenza vaccination acceptance among health-care workers: a nationwide survey. Vaccine. 2008, 26:1408-1410. 10.1016/j.vaccine.2008.01.049

9. Dedoukou X, Nikolopoulos G, Maragos A, Giannoulidou S, Maltezou HC: Attitudes towards vaccination against seasonal influenza of health-care workers in primary health-care settings in Greece. Vaccine. 2010, 28:5951-5953. 10.1016/j.vaccine.2010.06.108

10. Maltezou HC, Christophilea O, Tseleoni A, Katerelos P, Dounias G: Vaccination of healthcare workers against influenza: does a day off make a difference?. J Hosp Infect. 2018, 99:181-4. 10.1016/j.jhin.2018.01.014

11. Loerbroks A, Stock C, Bosch JA, Litaker DG, Apfelbacher CJ: Influenza vaccination coverage among high-risk groups in 11 European countries. Eur J Public Health. 2012, 22:562-8. 10.1093/eurpub/ckt994

12. Papagiannis D, Rachiotis G, Mariolis A, Zafiriou E, Gourgoulianis KI: Vaccination coverage of the elderly in Greece: a cross-sectional nationwide study. Can J Infect Dis Med Microbiol. 2020, 2020:5459793. 10.1155/2020/5459793

13. Verger P, Cortaredona S, Pulcini C, Casanova L, Peretti-Watel P, Launay O: Characteristics of patients and physicians correlated with regular influenza vaccination in patients treated for type 2 diabetes: a follow-up study from 2008 to 2011 in southeastern France. Clin Microbiol Infect. 2020, 25:950.e1-9. 10.1016/j.cmi.2015.06.017

14. Clancy U, Morani J, Tuthill A: Prevalence and predictors of influenza and pneumococcal vaccine uptake in patients with diabetes. Ir Med J. 2012, 105:298-300.

15. Tacken MA, Jansen B, Mulder J, Campbell SM, Braspenning JC: Dutch influenza vaccination rate drops for fifth consecutive year. Vaccine. 2015, 33:4886-91. 10.1016/j.vaccine.2015.07.052

16. Blank PR, van Essen GA, Ortiz de Lejarazu R, et al.: Impact of European vaccination policies on seasonal influenza vaccination coverage rates: an update seven years later. Hum Vaccin Immunother. 2018, 14:2706-14. 10.1080/21645515.2018.1489948

17. Jiménez-Trujillo I, López-de Andrés A, Hernández-Barrera V, Carrasco-Garrido P, Santos-Sancho JM, Jiménez-Garcia R: Influenza vaccination coverage rates among diabetes sufferers, predictors of adherence and time trends from 2005 to 2010 in Spain. Hum Vaccin Immunother. 2013, 9:1526-32. 10.4161/hv.23926

18. Johnson DR, Nichol KL, Lipczynski K: Barriers to adult immunization. Am J Med. 2008, 121:528-35. 10.1016/j.amjmed.2008.05.005

19. Ko YM, Ko SH, Han K, et al.: Importance of awareness and treatment for diabetes in Influenza vaccination coverage of diabetic patients under 65 years: a population-based study. Diabetes Metab J. 2021, 45:55-66.

20. Sotiropoulos A, Merkouris P, Gikas A, et al.: Influenza and pneumococcal vaccination rates among Greek diabetic patients in primary care. Diabet Med. 2005, 22:110-1. 10.1111/j.1464-5491.2005.01365.x